Does regular pharmacological treatment including inhaled corticosteroids (ICS) reduce mortality in patients with chronic obstructive pulmonary disease (COPD)? Few questions have attracted more attention in COPD, and the number of commentaries, editorials, and reviews on this topic by far exceeds the limited number of original papers addressing the topic. However, here is one more.

In this issue of the *Journal*, Lipson and colleagues (pp. [1508--1516](10.1164/rccm.201911-2207OC)) report findings from a *post hoc* analysis of the IMPACT (Informing the Pathway of COPD Treatment) trial ([@bib1]). The trial was enriched for exacerbators, and the primary outcome was the annual rate of on-treatment moderate and severe exacerbations comparing a fixed combination of fluticasone furoate (FF), umeclidinium (UMEC), and vilanterol (VI) with fixed combinations of UMEC/VI and FF/VI. Mortality was listed among "other efficacy outcomes" ([@bib2]), and the article presents an expanded analysis of mortality compared with the one reported in their primary report ([@bib3]). By obtaining information on vital status at end of the trial for an additional 574 patients, the authors had information on vital status for 10,313 of the 10,355 patients included in the trial. The authors compared mortality in patients randomized to FF/UMEC/VI with those randomized to either a fixed combination of FF/VI or a fixed combination of UMEC/VI. After 1 year, there were significantly fewer deaths in the triple-combination group (FF/UMEC/VI) than in the UMEC/VI group (absolute risk reduction \[ARR\], 0.83%; relative risk reduction \[RRR\], 28%; *P* = 0.042) but not when comparing the FF/VI group with the UMEC/VI group (ARR, 0.55%; RRR, 18%; *P* = 0.190). When analyses were restricted to on-treatment mortality, both these group analyses were statistically significant. The authors convincingly showed that missing outcome data on the 0.4% of the patient population were very unlikely to have had an impact on the reported estimates.

Only a few previous trials of an ICS-containing treatment have had mortality as a primary outcome. The TORCH (Toward a Revolution in COPD Health) study ([@bib4]) found a 2.6% ARR and a 17.5% RRR in deaths when comparing the combination of salmeterol and fluticasone propionate with placebo. However, the *P* value was adjusted from 0.041 to 0.052 to take a late interim analysis into account, and the study has since been referred to as "negative." The SUMMIT (Study to Understand Mortality and Morbidity) ([@bib5]) compared a combination of vilanterol and fluticasone furoate with placebo in patients with moderate COPD at heightened cardiovascular risk and could not demonstrate an effect on overall mortality (ARR, 0.7%; RRR, 12%; *P* = 0.137). Observational studies had previously indicated a beneficial effect of ICS on mortality, but these are all open to criticism as they lack randomization ([@bib6]). In neither TORCH nor SUMMIT did the long-acting β-agonist have any effect on mortality. In the UPLIFT (Understanding Potential Long-Term Impacts on Function with Tiotropium) trial, an effect on mortality, which was not the primary outcome, was likely present but depended on choice of analysis ([@bib7]). No other single study of a fixed triple combination has analyzed mortality, but a recent pooled *post hoc* analysis indicated a favorable effect on mortality of the fixed combination of extrafine beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide ([@bib8]).

It is unlikely that there will be any more studies of inhaled medications with mortality as primary outcome. Even though treatment before entering a study is unlikely to affect the study findings ([@bib9]), studies including patients who will have their existing treatment changed---and sometimes reduced---will always be open to criticism ([@bib10]). Studies of symptomatic treatment-naive patients with COPD are not possible, and placebo-controlled trials are unethical. Withdrawal from longer-term studies is inevitable and will dilute study findings ([@bib11]), and one could always question whether the findings from rigorous efficacy trials are transferable to usual clinical practice ([@bib12]). Nonetheless, the IMPACT findings are probably the best we will have, and we cannot shy away from having an opinion on the effects seen, with the usual "more studies are needed."

Now, should the discussion of these new IMPACT findings then focus on the small ARRs, the importance of the findings for the large patient group, the risk of pneumonia in the many versus the survival gain in the few, or the strengths and weaknesses of these findings? I would argue that this would be a waste of time. I would rather ask why we keep looking for reasons why a "proper" pharmacological treatment in COPD should *not* lead to a reduction in mortality in symptomatic COPD patients with a history of exacerbations. By "proper," I mean a treatment that affects lung function, health status, and frequency of moderate and severe exacerbations---which we can achieve with long-acting bronchodilators in the majority of patients and with ICS in a proportion of these ([@bib13]). To a COPD clinician it is clear that not all patients have marked benefits from the treatments, but to a vast number of patients, new long-acting inhaled drugs in simple combination inhalers have made a marked impact on their well-being and their ability to keep up with daily activities. Given what we know about risk factors for mortality in multimorbidity in general and COPD in particular, it really does not surprise me that these patients live longer. The challenge is now the same as for all other areas where individualized management is "the thing."

How do we provide ICS-containing treatment to those who will benefit the most with the fewest side effects, in particular pneumonia? Blood eosinophils is undoubtedly a step in the right direction ([@bib13], [@bib14]), but better understanding and application of this and future biomarkers could help us better identify those with the biggest benefit. In the meantime, we can appreciate that for patients with COPD with frequent exacerbations we can already provide treatments that make them live both better and longer.
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